Hormonal therapy in carcinoma of the kidney.
During the past 10 years we have studied 216 patients with renal cell carcinoma (RCC). After nephrectomy the patients were divided into two groups: one group received adjuvant acetate medroxyprogesterone therapy and the other formed our control group. The mean follow-up was 4.9 years. Survival was studied through univariate and multivariate analysis, according to Cox's multiple regression. To evaluate survival the following variables were taken into consideration: stage, grade, ploidy, sex, age, MAP therapy, Er, AR, PR receptors. The survival curves according to Kaplan and Meier were statistically significant for stage, grade, MAP therapy and DNA cellular content. The other variables were not statistically significant prognostic factors. Multivariate analysis demonstrated that only stage and MAP therapy are capable of influencing survival. A low stage has a better survival rate and in equivalent stages those who have received MAP live longer.
Di Silveiro
F
F
Department of Urology, University of Rome La Sapienza, Italy.
La Pera
G
G
De Matties
A
A
De Vita
R
R
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D008297:Male; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D015999:Multivariate Analysis; D009392:Nephrectomy; D011956:Receptors, Cell Surface / Q000032:analysis; D015996:Survival Rate
D004273:DNA, Neoplasm; D011956:Receptors, Cell Surface; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone